Ae
Aerpio Pharmaceutics
Blue Ash OHFounded 201130 employees
Private CapbiotechAcquiredOphthalmology
Platform: Tie2 DME
Market Cap
N/A
All Drugs
4
Clinical Trials
9
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Kemanesiran | AER-1372 | Phase 3 | 1 | CD19 | EoE | ||
| AER-8916 | AER-8916 | Approved | 2 | CD47 | GA | ||
| Lisoderotide | AER-6343 | Phase 3 | 4 | SHP2 | CLLFabry | ||
| Ceviosocimab | AER-9526 | NDA/BLA | 2 | FGFR | ACCCF |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (8)